AKIGAI
Private Company
Funding information not available
Overview
AKIGAI is a private, preclinical-stage biotech company founded in 2020 in Oslo, Norway, focused on developing disruptive drugs for neuropathic pain. The company's foundation is the serendipitous discovery and subsequent patenting of the use of EGFR inhibitors for neuropathic pain relief, supported by preclinical research and clinical observations in over 100 patients across 10 clinics. AKIGAI is pursuing a dual-path development strategy involving both tyrosine kinase inhibitors and monoclonal antibodies, and is actively seeking partners to advance its programs toward clinical validation and commercialization.
Technology Platform
Repurposing and development of EGFR (Epidermal Growth Factor Receptor) inhibitors, a class of oncology drugs, for the novel application of treating neuropathic pain, supported by a patented use and strong clinical observations.
Opportunities
Risk Factors
Competitive Landscape
AKIGAI faces competition from generic gabapentinoids/SNRIs and novel mechanism drugs from large pharma (e.g., Vertex). Its key differentiation lies in strong human proof-of-concept data (>100 patients), a novel non-CNS/non-addictive mechanism (EGFR inhibition), and patented use of an established drug class, offering a potentially faster path to an effective therapy.